Methods and compositions for treating inflammatory and fibrotic pulmonary disorders
AssigneesUniversity of Houston System, Board of Regents, The University of Texas System, Tract Pharmaceuticals, Inc.
InventorsFrank McKEON, Wei RAO, Jingzhong XIE, Shan WANG, Wa XIAN, Matthew VINCENT, Suchan NIROULA
Life of this patent
Estimating the term…
Abstract
The present disclosure addresses inflammatory lung diseases, such as COPD, and fibrotic lung diseases such as idiopathic pulmonary fibrosis, from the standpoint of inhibiting or ablating pathogenic epithelial stem cells found in the pulmonary tract.
Claims35
A method for treating a patient presenting with one or more of an inflammatory disease, metaplasia, dysplasia or cancer of pulmonary tissues which method comprises administering to the patient an agent that selectively kills or inhibits the proliferation or induces differentiation of pathogenic lung epithelial stem cells (PLESCs) relative to normal pulmonary stem cells.
A method of reducing proliferation, survival, migration, or colony formation ability of pathogenic lung epithelial stem cells (PLESCs) in a subject in need thereof comprising contacting the cell with a therapeutically effective amount of an agent that selectively kills or inhibits the proliferation or induces differentiation of PLESC relative to normal pulmonary stem cells.
A pharmaceutical preparation for treating one or more of an inflammatory disease, metaplasia, dysplasia or cancer of pulmonary tissues, the preparation comprises an agent that selectively kills or inhibits the proliferation or induces differentiation of pathogenic lung epithelial stem cells (PLESCs) relative to normal pulmonary stem cells.
A pulmonary delivery device for treating one or more of an inflammatory disease, metaplasia, dysplasia or cancer of pulmonary tissues, which device comprises an inhalation formulation of an agent that selectively kills or inhibits the proliferation or induces differentiation of pathogenic lung epithelial stem cells (PLESCs) relative to normal pulmonary stem cells, which device delivers a dose of the agent to the afflicted lung tissue;
- wherein the pulmonary delivery device is optionally a metered dose inhaler, a nebulizer or a dry powder inhaler.
Dependencies are inferred from the claim text.